immatics is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer.
Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies.
We aim to achieve this by using multiple and relevant peptides that specifically activate T cells, specialized white blood cells, of the patient’s immune system against cancer cells. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors.
Our lead product, IMA901 for the treatment of kidney cancer, is in a global phase 3 clinical trial. Our other clinical-stage products are IMA910 for the treatment of colorectal cancer, which has completed a multi-center phase 2 clinical trial, and IMA950 for the treatment of brain cancer, which is in phase 1 clinical studies with partners. We also have active early-stage programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer being developed in collaboration with our partner Roche.
- -- 07 March 2014
immatics presents at BioEurope Spring 2014 (March 10-12, 2014) in Turin, Italy
- Monday, March 10 5.15pm – 6.15pm From pariah to darling: Biopharma finally courts ... read more
- -- 04 February 2014
immatics congratulates immatics’ co-founder Hans-Georg Rammensee for receiving the Award of the Deutsche Krebshilfe (German Cancer Aid Award)
- Less than a year after receiving the ... read more
- -- 24 January 2014
immatics presents at the 6th Immunotherapeutics & Immunomonitoring Conference (Jan. 30-31, 2014) in San Diego, CA, USA
- Thursday, January 30 4.35pm – 5.00pm The GAPVAC Consortium: Making Personalized Cancer ... read more
Renal cell cancer phase 3 clinical trial
Drug: Peptide-based renal cell cancer vaccine IMA901...read more
Participating countries: France, Germany, Hungary, Italy, Poland, Russia, UK, USA, Netherlands, Norway
Glioblastoma phase 1 clinical trials
Drug: Peptide-based glioma vaccine IMA950...read more
Participating countries: UK & USA
Selected immatics publications
immatics fact sheet